(((2-(2,2-dimethoxyethyl)propane-1,3-diyl)bis(oxy))bis(methylene))dibenzene | 99776-33-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (((2-(2,2-dimethoxyethyl)propane-1,3-diyl)bis(oxy))bis(methylene))dibenzene
• 英文别名: benzyl 2-(benzyloxymethyl)-4,4-dimethoxybutyl ether；Benzyl 2-benzyloxymethyl-4,4-dimethoxybutyl ether；[4,4-dimethoxy-2-(phenylmethoxymethyl)butoxy]methylbenzene
• CAS: 99776-33-7
• 化学式: C₂₁H₂₈O₄
• 分子量: 344.451
• InChiKey: AIVKEPXGVLLDID-UHFFFAOYSA-N

物化性质

• 沸点：
  443.0±45.0 °C(Predicted)
• 密度：
  1.060±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  25
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  36.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (((2-(2,2-dimethoxyethyl)propane-1,3-diyl)bis(oxy))bis(methylene))dibenzene 在 palladium on activated charcoal 乙醇 、 氢气 、 sodium acetate 、 三氟乙酸 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 、 水 为溶剂， 反应 37.5h， 生成 2-<4-benzyloxy(3-benzyloxymethyl)butyl>-3-(cyanomethyleneamino)acrylonitrile
  参考文献：
  名称：

  Buchanan, J. Grant; Craven, David A.; Wightman, Richard H., Journal of the Chemical Society. Perkin transactions I, 1991, # 1, p. 195 - 202

  摘要：

  DOI：
• 作为产物：
  描述：

  diethyl 2-(2,2-dimethoxyethyl)malonate 在 lithium aluminium tetrahydride 、 sodium hydride 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 37.5h， 生成 (((2-(2,2-dimethoxyethyl)propane-1,3-diyl)bis(oxy))bis(methylene))dibenzene
  参考文献：
  名称：

  Rational hopping of a peptidic scaffold into non-peptidic scaffolds: structurally novel potent proteasome inhibitors derived from a natural product, belactosin A

  摘要：

  基于构建的药效团模型，对天然产物belactosin A衍生物进行合理的支架跳跃，最终导致识别出明显简化的高效非肽衍生物。

  DOI：

  10.1039/c3cc48818g

文献信息

• Guanine derivative
  申请人：Astra Lakemedel Aktiebolag

  公开号：US04798833A1

  公开（公告）日：1989-01-17

  Antivirally active compounds of the formula ##STR1## wherein A is ##STR2## wherein m is 1 or 2, n is 1 or 2, whereby m is 1 when n is 2 and m is 2 when n is 1, R.sub.a ' is (CH.sub.2).sub.p OH, NHCONH.sub.2 or COR.sub.a ", R.sub.a " is hydrogen, hydroxy or amino, p is 1 to 4, R.sub.b ' and R.sub.b " are independently selected from hydrogen or (CH.sub.2).sub.p OH, with the proviso that at least one of R.sub.b ' or R.sub.b " is hydrogen; or R.sub.b ' and R.sub.b " together constitute an additional carbon-carbon bond to form an alkyne; or a physiologically acceptable salt, geometric or optical isomer thereof; pharmaceutical preparations containing the compounds and methods for treatment of virus infections.

  该公式代表的抗病毒活性化合物，其中A是，m为1或2，n为1或2，当n为2时m为1，当n为1时m为2，R.sub.a '为(CH.sub.2).sub.p OH，NHCONH.sub.2或COR.sub.a "，R.sub.a "为氢、羟基或氨基，p为1至4，R.sub.b '和R.sub.b "分别选择自氢或(CH.sub.2).sub.p OH，但至少其中一个为氢；或R.sub.b '和R.sub.b "一起构成额外的碳-碳键形成炔烃；或其生理上可接受的盐、几何或光学异构体；含有该化合物的药物制剂和治疗病毒感染的方法。
• Derivatives of Guanine, process for their preparation and a pharmaceutical preparation
  申请人：Astra Läkemedel Aktiebolag

  公开号：EP0146516A2

  公开（公告）日：1985-06-26

  Antivirally active compounds of the formula wherein A is or wherein: m is 1 or 2, n is 1 or 2, whereby m is 1 when n is 2 and m is 2 when n is 1, R'a is (CH2)pOH, NHCONH2 or COR"a, R"a is hydrogen, hydroxy or amino, p is 1 to 4, R'b and R" are independently selected from hydrogen or (CH2)pOH, with the proviso that at least one of R'b or R"b is hydrogen; or R'b and R"b together constitute an additional carbon-carbon bond to form an alkyne; or a physiologically acceptable salt, geometric or optical isomer thereof; processes for preparation of said compounds, pharmaceutical preparations containing the compounds, methods for treatment of virus infections and the medical use of the compounds.

  式中A为 或 的抗病毒活性化合物 其中：m为1或2，n为1或2，其中n为2时m为1，n为1时m为2，R'a为(CH2)pOH、NHCONH2或COR "a，R "a为氢、羟基或氨基，p为1至4，R'b和R "独立地选自氢或(CH2)pOH，但R'b或R "b中至少有一个为氢；或R'b和R "b共同构成额外的碳-碳键以形成炔；或其生理上可接受的盐、几何或光学异构体；制备所述化合物的工艺、含有所述化合物的药物制剂、治疗病毒感染的方法以及所述化合物的医疗用途。
• Pandit,U.K. et al., Synthetic Communications, 1972, vol. 2, p. 345 - 351
  作者：Pandit,U.K. et al.

  DOI：——

  日期：——
• Structurally Novel Highly Potent Proteasome Inhibitors Created by the Structure-Based Hybridization of Nonpeptidic Belactosin Derivatives and Peptide Boronates
  作者：Shuhei Kawamura、Yuka Unno、Akira Asai、Mitsuhiro Arisawa、Satoshi Shuto

  DOI：10.1021/jm500045x

  日期：2014.3.27

  We previously developed highly potent proteasome inhibitor 1 (IC50 = 5.7 nM) and its nonpeptide derivative 2 (IC50 = 29 nM) by systematic structure-activity relationship studies of the peptidic natural product belactosin A and subsequent rational topology-based scaffold hopping, respectively. Their cell growth inhibitory activities, however, were only moderate (IC50 = 1.8 μM (1) and >10 μM (2)). We therefore planned to replace the unstable β-lactone warhead with a more stable boronic acid warhead. Importantly, belactosin derivatives bind mainly to the proteasome binding site, which is different from that occupied by known peptide boronate proteasome inhibitors such as bortezomib, suggesting that their hybridization might lead to the development of novel potent inhibitors. Here we describe design, synthesis, and biological activities of the newly developed potent hybrid proteasome inhibitors. Interestingly, these hybrids, unlike bortezomib, were highly selective for proteasomes and have long residence times despite having the same boronic acid warhead.
• BUCHANAN, J. GRANT;CRAVEN, DAVID A.;WIGHTMAN, RICHARD H.;HARNDEN, MICHAEL+, J. CHEM. SOC. PERKIN TRANS. PT 1,(1991) N, C. 195-202
  作者：BUCHANAN, J. GRANT、CRAVEN, DAVID A.、WIGHTMAN, RICHARD H.、HARNDEN, MICHAEL+

  DOI：——

  日期：——